A phase II dose-ranging study of mirabegron in patients with overactive bladder

被引：0
|
作者：
Christopher R. Chapple
Vladimir Dvorak
Pjotr Radziszewski
Philip Van Kerrebroeck
Jean Jacques Wyndaele
Brigitte Bosman
Peter Boerrigter
Ted Drogendijk
Arwin Ridder
Ingrid Van Der Putten-Slob
Osamu Yamaguchi
机构：
[1] Sheffield Teaching Hospitals,Department of Urology, Royal Hallamshire Hospital
[2] Centrum ambulantní gynekologie a primární péce,Department of Urology
[3] Medical University Warsaw,Department Urology
[4] Maastricht University Medical Center,Department of Urology
[5] Antwerp University and Antwerp University Hospital,Division of Bioengineering and LUTD Research, School of Engineering
[6] Astellas Pharma Europe BV,undefined
[7] Nihon University,undefined
来源：
International Urogynecology Journal | 2013年 / 24卷
关键词：
β; -adrenoceptor agonist; Mirabegron; Overactive; Urinary bladder;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1447 / 1458
页数：11
相关论文
共 50 条
  • [31] A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group)
    Shiraki, M
    Fukunaga, M
    Kushida, K
    Kishimoto, H
    Taketani, Y
    Minaguchi, H
    Inoue, T
    Morita, R
    Morii, H
    Yamamoto, K
    Ohashi, Y
    Orimo, H
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 (03) : 225 - 234
  • [32] Mirabegron: A Review of Its Use in Patients with Overactive Bladder Syndrome
    Mark Sanford
    Drugs, 2013, 73 : 1213 - 1225
  • [33] EFFECT OF DOSE ON EFFICACY AND SAFETY IN IPILIMUMAB-TREATED PATIENTS WITH ADVANCED MELANOMA - RESULTS FROM A PHASE II, RANDOMIZED, DOSE-RANGING STUDY
    Lebbe, C.
    Hoos, A.
    Chin, K.
    Li, J.
    Neyns, B.
    Linette, G.
    Negrier, S.
    Schadendorf, D.
    Smylie, M.
    Wolchok, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 239 - 240
  • [34] HPG1860 in patients with NASH: a phase II double-blind, placebo-controlled, dose-ranging study
    Alkhouri, Naim
    Liu, Yongheng
    Liang, Nian
    Zhai, Peibin
    Wu, Sandra
    Zhou, Xin
    Xu, Michael
    Liu, Que
    Harrison, Stephen
    JOURNAL OF HEPATOLOGY, 2023, 78 : S812 - S812
  • [35] A double-blind, randomized, multicenter, dose-ranging phase II study of the misoprostol vaginal insert
    Powers, Barbara
    Parker, Lamar
    Miller, Hugh
    Wing, Deborah A.
    Rayburn, William
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2011, 204 : S48 - S48
  • [36] A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS
    Chang, L
    Ameen, VZ
    Dukes, GE
    McSorley, DJ
    Carter, EG
    Mayer, EA
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (01): : 115 - 123
  • [37] Effects of Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder
    Kinjo, Manami
    Yamaguchi, Tsuyoshi
    Tambo, Mitsuhiro
    Okegawa, Takatsugu
    Fukuhara, Hiroshi
    UROLOGIA INTERNATIONALIS, 2019, 102 (03) : 331 - 335
  • [38] Mirabegron: A Review of Its Use in Patients with Overactive Bladder Syndrome
    Sanford, Mark
    DRUGS, 2013, 73 (11) : 1213 - 1225
  • [39] A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities
    Danilov, Alexey V.
    Lewis, Lionel D.
    Lansigan, Frederick
    Roudaia, Liya
    Findley, Darcie L.
    Jones, Susan Y.
    Highhouse, Brian
    Beaulieu, Bernard B.
    Brown, Jennifer R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (05) : 820 - 823
  • [40] Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
    van der Heijde, Desiree
    Deodhar, Atul
    Wei, James C.
    Drescher, Edit
    Fleishaker, Dona
    Hendrikx, Thijs
    Li, David
    Menon, Sujatha
    Kanik, Keith S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (08) : 1340 - 1347
12345